Sepracor receives approval for new drug
By HME News Staff
Updated Sun October 15, 2006
MARLBOROUGH, Mass. - Sepracor's shares rose 59 cents to $50.79 last Monday, after the Food and Drug Administration approved the drug-maker's new respiratory medication about six months earlier than expected.
Brovana is the first long-acting beta2 agonist approved for use in an inhaler and is the first new nebulizer medication to hit the market in several years. Developed as a more user friendly, twice-daily treatment, Brovana is expected to improve patient compliance rates.
The drug has garnered favorable reviews among industry watchers, who believe the drug could provide a boost to the industry, which has suffered several blows over the past year, including a sharp dispensing fee cut; a proposal to reimburse brand-name drugs at generic rates; and a plan to cut payments to compounding pharmacies beginning in January 2007.
Sepracor plans to launch Brovana during the second quarter of 2007.
Comments